Therapeutic effect of Jianpi Liqi Fang(健脾理气方)combined with transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and spleen deficiency syndrome  

作　　者：CHEN Xiaole WANG Peng MENG Zhiqiang YANG Mengdie ZHOU Wenjun SU Shibing CHEN Jian 

机构地区：[1]Research Center for Traditional Chinese Medicine Complexity System,Institute of Interdisciplinary Integrative Medicine Research,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China [2]Department of Liver and Spleen and Stomach Diseases,Henan Province Hospital of Traditional Chinese Medicine/the Second Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450002 Henan,China [3]Department of Integrative Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China [4]Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China [5]Shanghai TCM-Integrated Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200082,China [6]Shanghai TCM-Integrated Institute of Vascu-lar Anomalies,Shanghai 200082,China [7]Institute of Vasdular Anomalies,Shanghai Academy of Traditional Chinese Medi-cine,Shanghai 200082,China

出　　处：《Journal of Traditional Chinese Medicine》2021年第1期157-166,共10页中医杂志（英文版）

基　　金：Supported by Key Program of National Science Foundation of China:study of’same syndrome in different diseases’and same treatment in different diseases’of hepatocellular carcinoma and colorectal cancer based on systems biology(No.81330084)。

摘　　要：OBJECTIVE:To investigate the therapeutic effect of the Jianpi Liqi Fang(健脾理气方,JPLQF)combined with transcatheter arterial chemoembolization(TACE)in patients with hepatocellular carcinoma(HCC)and spleen deficiency syndrome(SDS)and identify a potential indicator of efficacy.METHODS:Ninety-nine patients with HCC who were diagnosed with SDS,non-spleen deficiency syndrome(NSDS),or no syndrome(NS)were treated with JPLQF combined with TACE for three periods.Therapeutic efficacy was compared among the groups.Plasma proteins were screened using label-free discovery analysis and verified via enzyme-linked immunosorbent assay(ELISA).Furthermore,receiver operating characteristic(ROC)curves were analyzed to evaluate therapeutic indicators.RESULTS:After treatment,the Karnofsky Performance Status was significantly improved in the SDS group and significantly better than that in the NS group.The Traditional Chinese Medicine(TCM)syndrome scores were lower in the SDS group after treatment and lower than those in the NSDS group.However,alanine aminotransferase,carbohydrate antigen 19-9,alpha-fetoprotein,and carcinoembryonic antigen levels and white blood cell and platelet counts did not differ among the groups.Serum aspartate aminotransferase levels in the SDS group were significantly lower after treatment than before treatment,and total bilirubin levels were significantly lower in the SDS group than in the NSDS group.Label-free analysis identified 24 differentially expressed proteins(DEPs)between the SDS and NS groups,including 17 and 7 upregulated and downregulated proteins,respectively.Fibulin-5(FBLN5)displayed the largest difference in expression between the groups.ELISA confirmed that FBLN5 levels were significantly lower in the NSDS and NS groups than in the SDS group.Following treatment with JPLQF and TACE,FBLN5 expression was upregulated only in the SDS group.Furthermore,ROC curve analysis indicated that FBLN5 may serve as a potential indicator of the efficacy of JPLQF combined with TACE in patients with HCC and SDS

关 键 词：Carcinoma hepatocellular drugs Chinese herbal PROTEOMICS indicators and reagents FIBULIN-5 

分 类 号：R735.7[医药卫生—肿瘤]